96 related articles for article (PubMed ID: 15863158)
1. Transforming growth factor beta receptor I polyalanine repeat polymorphism does not increase ovarian cancer risk.
Spillman MA; Schildkraut JM; Halabi S; Moorman P; Calingaert B; Bentley RC; Marks JR; Murphy S; Berchuck A
Gynecol Oncol; 2005 May; 97(2):543-9. PubMed ID: 15863158
[TBL] [Abstract][Full Text] [Related]
2. TGFBR1*6A and cancer risk: a meta-analysis of seven case-control studies.
Kaklamani VG; Hou N; Bian Y; Reich J; Offit K; Michel LS; Rubinstein WS; Rademaker A; Pasche B
J Clin Oncol; 2003 Sep; 21(17):3236-43. PubMed ID: 12947057
[TBL] [Abstract][Full Text] [Related]
3. Polymorphisms in BRCA1 and BRCA2 and risk of epithelial ovarian cancer.
Wenham RM; Schildkraut JM; McLean K; Calingaert B; Bentley RC; Marks J; Berchuck A
Clin Cancer Res; 2003 Oct; 9(12):4396-403. PubMed ID: 14555511
[TBL] [Abstract][Full Text] [Related]
4. TbetaR-I(6A) is a candidate tumor susceptibility allele.
Pasche B; Kolachana P; Nafa K; Satagopan J; Chen YG; Lo RS; Brener D; Yang D; Kirstein L; Oddoux C; Ostrer H; Vineis P; Varesco L; Jhanwar S; Luzzatto L; Massagué J; Offit K
Cancer Res; 1999 Nov; 59(22):5678-82. PubMed ID: 10582683
[TBL] [Abstract][Full Text] [Related]
5. Combined genetic assessment of transforming growth factor-beta signaling pathway variants may predict breast cancer risk.
Kaklamani VG; Baddi L; Liu J; Rosman D; Phukan S; Bradley C; Hegarty C; McDaniel B; Rademaker A; Oddoux C; Ostrer H; Michel LS; Huang H; Chen Y; Ahsan H; Offit K; Pasche B
Cancer Res; 2005 Apr; 65(8):3454-61. PubMed ID: 15833881
[TBL] [Abstract][Full Text] [Related]
6. Progesterone receptor promoter +331A polymorphism is associated with a reduced risk of endometrioid and clear cell ovarian cancers.
Berchuck A; Schildkraut JM; Wenham RM; Calingaert B; Ali S; Henriott A; Halabi S; Rodriguez GC; Gertig D; Purdie DM; Kelemen L; Spurdle AB; Marks J; Chenevix-Trench G
Cancer Epidemiol Biomarkers Prev; 2004 Dec; 13(12):2141-7. PubMed ID: 15598772
[TBL] [Abstract][Full Text] [Related]
7. Lack of an association between the TGFBR1*6A variant and colorectal cancer risk.
Skoglund J; Song B; Dalén J; Dedorson S; Edler D; Hjern F; Holm J; Lenander C; Lindforss U; Lundqvist N; Olivecrona H; Olsson L; Påhlman L; Rutegård J; Smedh K; Törnqvist A; Houlston RS; Lindblom A
Clin Cancer Res; 2007 Jun; 13(12):3748-52. PubMed ID: 17575241
[TBL] [Abstract][Full Text] [Related]
8. Vitamin D receptor gene polymorphisms and epithelial ovarian cancer risk.
Lurie G; Wilkens LR; Thompson PJ; McDuffie KE; Carney ME; Terada KY; Goodman MT
Cancer Epidemiol Biomarkers Prev; 2007 Dec; 16(12):2566-71. PubMed ID: 18086759
[TBL] [Abstract][Full Text] [Related]
9. Polymorphisms in the promoter regions of the matrix metalloproteinases-1, -3, -7, and -9 and the risk of epithelial ovarian cancer in China.
Li Y; Jin X; Kang S; Wang Y; Du H; Zhang J; Guo W; Wang N; Fang S
Gynecol Oncol; 2006 Apr; 101(1):92-6. PubMed ID: 16278009
[TBL] [Abstract][Full Text] [Related]
10. Progesterone receptor (PROGINS) polymorphism and the risk of ovarian cancer.
Leite DB; Junqueira MG; de Carvalho CV; Massad-Costa AM; Gonçalves WJ; Nicolau SM; Lopes LA; Baracat EC; da Silva ID
Steroids; 2008 Jul; 73(6):676-80. PubMed ID: 18384825
[TBL] [Abstract][Full Text] [Related]
11. No relationship between ovarian cancer risk and progesterone receptor gene polymorphism in a population-based, case-control study in North Carolina.
Lancaster JM; Wenham RM; Halabi S; Calingaert B; Marks JR; Moorman PG; Bentley RC; Berchuck A; Schildkraut JM
Cancer Epidemiol Biomarkers Prev; 2003 Mar; 12(3):226-7. PubMed ID: 12646513
[No Abstract] [Full Text] [Related]
12. The TGFBR1*6A/9A polymorphism is not associated with differential risk of breast cancer.
Colleran G; McInerney N; Rowan A; Barclay E; Jones AM; Curran C; Miller N; Kerin M; Tomlinson I; Sawyer E
Breast Cancer Res Treat; 2010 Jan; 119(2):437-42. PubMed ID: 19390964
[TBL] [Abstract][Full Text] [Related]
13. Transforming growth factor beta receptor 1 polyalanine polymorphism and exon 5 mutation analysis in breast and ovarian cancer.
Baxter SW; Choong DY; Eccles DM; Campbell IG
Cancer Epidemiol Biomarkers Prev; 2002 Feb; 11(2):211-4. PubMed ID: 11867510
[No Abstract] [Full Text] [Related]
14. PGR +331 A/G and increased risk of epithelial ovarian cancer.
Risch HA; Bale AE; Beck PA; Zheng W
Cancer Epidemiol Biomarkers Prev; 2006 Sep; 15(9):1738-41. PubMed ID: 16985038
[TBL] [Abstract][Full Text] [Related]
15. The N314D polymorphism of galactose-1-phosphate uridyl transferase does not modify the risk of ovarian cancer.
Fung WL; Risch H; McLaughlin J; Rosen B; Cole D; Vesprini D; Narod SA
Cancer Epidemiol Biomarkers Prev; 2003 Jul; 12(7):678-80. PubMed ID: 12869412
[TBL] [Abstract][Full Text] [Related]
16. Type I transforming growth factor beta receptor maps to 9q22 and exhibits a polymorphism and a rare variant within a polyalanine tract.
Pasche B; Luo Y; Rao PH; Nimer SD; Dmitrovsky E; Caron P; Luzzatto L; Offit K; Cordon-Cardo C; Renault B; Satagopan JM; Murty VV; Massagué J
Cancer Res; 1998 Jul; 58(13):2727-32. PubMed ID: 9661882
[TBL] [Abstract][Full Text] [Related]
17. Increased risk of ovarian cancer in integrin beta3 Leu33Pro homozygotes.
Bojesen SE; Kjaer SK; Høgdall EV; Thomsen BL; Høgdall CK; Blaakaer J; Tybjaerg-Hansen A; Nordestgaard BG
Endocr Relat Cancer; 2005 Dec; 12(4):945-52. PubMed ID: 16322334
[TBL] [Abstract][Full Text] [Related]
18. A study on the association of cytochrome-P450 1A1 polymorphism and breast cancer risk in north Indian women.
Singh V; Rastogi N; Sinha A; Kumar A; Mathur N; Singh MP
Breast Cancer Res Treat; 2007 Jan; 101(1):73-81. PubMed ID: 16807674
[TBL] [Abstract][Full Text] [Related]
19. An investigation of relationships between hypoxia-inducible factor-1 alpha gene polymorphisms and ovarian, cervical and endometrial cancers.
Konac E; Onen HI; Metindir J; Alp E; Biri AA; Ekmekci A
Cancer Detect Prev; 2007; 31(2):102-9. PubMed ID: 17418979
[TBL] [Abstract][Full Text] [Related]
20. Two functionally relevant polymorphisms in the human progesterone receptor gene (+331 G/A and progins) and the predisposition for breast and/or ovarian cancer.
Romano A; Lindsey PJ; Fischer DC; Delvoux B; Paulussen AD; Janssen RG; Kieback DG
Gynecol Oncol; 2006 May; 101(2):287-95. PubMed ID: 16360811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
